These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32030214)

  • 21. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
    Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
    J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
    Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW
    J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative Study of PD-L1 Expression in Different Sites of 
Non-small Cell Lung Cancer].
    Huang X; Wu J; Zhou L; Song Z; Xu W; Jia L; Diao X; Wu Q; Lin D
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):303-310. PubMed ID: 35570146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
    Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
    Pan Y; Zheng D; Li Y; Cai X; Zheng Z; Jin Y; Hu H; Cheng C; Shen L; Wang J; Ji H; Sun Y; Zhou X; Chen H
    J Thorac Dis; 2017 Aug; 9(8):2579-2586. PubMed ID: 28932565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives.
    Kim SY; Kim TE; Park CK; Yoon HK; Sa YJ; Kim HR; Woo IS; Kim TJ
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
    Ilié M; Ngo-Mai M; Long-Mira E; Lassalle S; Butori C; Bence C; Hamila M; Hofman V; Hofman P
    J Vis Exp; 2018 Sep; (139):. PubMed ID: 30320751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
    Shen X; Wang Y; Jin Y; Zheng Q; Shen L; Chen Y; Li Y
    J Thorac Dis; 2021 Jul; 13(7):4360-4370. PubMed ID: 34422362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
    Basu A; Chiriboga L; Narula N; Zhou F; Moreira AL
    J Histotechnol; 2020 Dec; 43(4):174-181. PubMed ID: 33245263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
    Dietel M; Savelov N; Salanova R; Micke P; Bigras G; Hida T; Antunez J; Guldhammer Skov B; Hutarew G; Sua LF; Akita H; Chan OSH; Piperdi B; Burke T; Khambata-Ford S; Deitz AC
    Lung Cancer; 2019 Aug; 134():174-179. PubMed ID: 31319978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
    Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
    J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G; Huang L; Emancipator K; Nuti S
    PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
    Roach C; Zhang N; Corigliano E; Jansson M; Toland G; Ponto G; Dolled-Filhart M; Emancipator K; Stanforth D; Kulangara K
    Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):392-7. PubMed ID: 27333219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
    Yeong J; Lum HYJ; Teo CB; Tan BKJ; Chan YH; Tay RYK; Choo JR; Jeyasekharan AD; Miow QH; Loo LH; Yong WP; Sundar R
    Gastric Cancer; 2022 Jul; 25(4):741-750. PubMed ID: 35661944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types.
    Krigsfeld GS; Prince EA; Pratt J; Chizhevsky V; William Ragheb J; Novotny J; Huron D
    J Clin Pathol; 2020 Oct; 73(10):656-664. PubMed ID: 32591352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.